$AMPX

Why is Amprius Technologies stock surging today?

Amprius Technologies (AMPX) shares rose about 8.1% pre-open after the company reported Q2 2026 revenue of $34.0M, up 126% year over year, beating expectations. Amprius raised full-year 2026 revenue guidance to at least $140.0M, while targeting net loss under $10.0M and non-GAAP Adjusted EBITDA of at least $4.0M. GAAP EPS missed due to a warrant modification impact.

Original reporting
Published Aug 5, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:16 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$AMPX
Bullish
medium confidence
Mentioned
$AMPX
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$AMPXBullishMed
01

Why it matters

Traders can treat this as a fresh earnings-and-guidance catalyst for AMPX, with the key debate likely centered on GAAP EPS optics versus underlying operating trajectory and the credibility of the production ramp implied by guidance.

02

Market read

Revenue beat and guidance raise are the immediate drivers for AMPX’s same-day repricing, with sentiment supported by modestly positive broader market action.

03

What to watch

Follow-through may depend on whether the raised revenue outlook is supported by sustained gross margin improvement and production ramp execution, not just the quarter’s beat.

Relevance 8/10Novelty 8/10Timing: pre-open today after prior evening Q2 results and guidance raise

Background

The piece attributes Amprius’s pre-market jump to its Q2 2026 results and an upgraded 2026 revenue outlook, with commentary on margins and loss metrics.

Company-level read

Ticker impact

$AMPXBullishMedium confidence
Context

Amprius reported Q2 2026 revenue of $34.0M (+126% YoY) and raised full-year 2026 revenue guidance to at least $140.0M, driving an 8.1% pre-open surge.

Expected impact

Near-term bias higher while traders digest the raised revenue outlook and margin trajectory; volatility possible around GAAP EPS optics.

Evidence & confidence

The article cites concrete, time-sensitive fundamentals (revenue beat, guidance raise, gross margin commentary) as the catalyst for the same-session move, but it also flags GAAP EPS optics and non-cash items that can temper follow-through.

Market effects

Reinforces investor appetite for silicon anode and advanced battery suppliers tied to defense and drone demand.

Primarily US small-cap growth sentiment, with broader indices modestly supportive.

Limited direct global linkage beyond defense/drone supply chain read-through.

Counterpoint

The GAAP EPS miss could reassert if investors focus on headline losses rather than the non-cash warrant modification and non-GAAP framing.

Key entities

  • Amprius Technologies

    Silicon anode battery maker reporting Q2 2026 results and raising full-year 2026 revenue guidance.

  • Ricardo C. Rodriguez

    CFO quoted describing the quarter as strong and highlighting gross margin progress.

  • Northland Securities

    Flagged the prior selloff as an attractive entry point, preceding the sharp pre-market reaction.

Related articles

$AMPXHigh

Amprius Technologies, Inc. (AMPX): Results of Operations and Financial Condition

Amprius Technologies, Inc. (AMPX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ampx-2026x08x04x8kex991.htm EX-99.1 Document Exhibit 99.1 Amprius Technologies Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Q2 2026 revenue more than doubled year-over-year to $34.0 million. • Net loss of $5.1 million, representing a 20

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.

$CPTMedAI 8/10

Camden Property Trust (CPT) Q2 2026 Earnings Call Transcript

Camden Property Trust (CPT) discussed its Q2 2026 earnings call, focusing on exiting its California multifamily portfolio. According to management, it sold the 19-year-old California portfolio for $1.625 billion, with trailing 12-month FFO and AFFO yields of 5.6% and 5.2%. Camden repurchased $694 million of shares and closed $645 million of acquisitions plus $195 million of awarded acquisitions, reaffirming $6.75/share FFO guidance.